Despite COVID-19, we are operating at full capacity and all project work is operating as usual.

Clinically predictive preclinical efficacy testing services at your disposal

SEPTEMBER 13, 2013

Pharmatest Services Ltd launches new preclinical osteoarthritis models

[Updated October 4, 2013] Turku, Finland -based CRO Pharmatest Services Ltd launches new fully validated preclinical efficacy models for osteoarthritis that were developed in a Eurostars-funded project during 2009 – 2013.  The validation results will be presented in the ASBMR annual meeting in Baltimore, MD, during October 4 – 7.

Osteoarthritis (OA) is the most common joint disease and among the most common causes of chronic pain and disability in older people, affecting 12.6% of total population in Western countries. No disease modifying treatment options for OA are currently available, and development of OA drugs is of increasing interest to the pharmaceutical industry.

Pharmatest Services Ltd (Pharmatest) is a contract research organization (CRO) that offers preclinical efficacy services for the pharmaceutical industry in the fields of skeletal diseases and oncology. Annual meeting of the American Society for Bone and Mineral Research (ASBMR) is the globally leading scientific event in bone research.

This year Pharmatest attends ASBMR in Baltimore, MD, on October 4 – 7, and presents scientific presentations that include results of validation studies of four new preclinical OA models. With the current announcement Pharmatest officially launches the models as service products for the pharmaceutical industry developing new treatment options for OA.

Jussi Halleen, CEO of Pharmatest comments: “We want to thank our Dutch partner Percuros for fruitful collaboration in the project, and the Eurostars programme for the funding. Without them we would not have these new OA models ready now. I am convinced that these models will have a substantial impact in the growth of our business, and we will be able to help the pharma industry in developing new OA treatments and battling the increasing disease burden of OA in the coming years.”

The data was published in a poster presentation for the first time on October 3, 2013 at the ASBMR Symposium: Cutting Edge Discoveries in Muscle Biology, Disease and Therapeutics after an invitation from the organizers (poster P018). The poster will be presented a second time in poster session III of ASBMR regular program at the Discovery Hall-Hall CDE, Baltimore Convention Center (poster MO0013), titled " Degenerative Changes in Knee Joints and Joint Pain in Surgically and Chemically Induced Rat Models of Osteoarthritis".